A global physician survey found that six in ten doctors believe men are more likely to die from stroke than women, despite women being 11% more likely to die from the condition. The study highlights the importance of addressing hypertension as a major risk factor for strokes and improving awareness among women about their risk factors.
A study published in MERCURY I showed that CRESTOR 10mg effectively lowered LDL-C levels and enabled over eight out of ten patients to achieve their LDL-C goals. The medication demonstrated superior efficacy compared to atorvastatin, making it a valuable treatment option for managing high cholesterol and reducing cardiovascular risk.
A study by Professor Melissa DelBello found that quetiapine added to divalproex reduced psychotic symptoms in significantly more patients than divalproex alone. The quetiapine combination group also showed improved outcomes without treatment-emergent extrapyramidal symptoms.
A survey of practice nurses found that 85% are underestimating the prevalence of insulin resistance in type 2 diabetes patients. This lack of awareness can lead to inadequate treatment and education, highlighting the need for increased understanding of insulin resistance as a fundamental cause of type 2 diabetes.
A survey found that nearly two-thirds of GPs are unaware that insulin resistance is present in 92% of people with type 2 diabetes. This lack of understanding can lead to suboptimal treatment, as insulin resistance improves glycaemic control and reduces cardiovascular complications.
New research presents preliminary results of a study on Xenical's effectiveness in promoting rapid and sustained weight loss. The medication has been shown to improve cardiovascular risk factors and maintain weight loss for up to two years, resulting in significant health benefits.
New studies announce that AVANDIA (rosiglitazone maleate) may significantly reduce insulin resistance and lower cardiovascular risk in Type 2 diabetes patients. Insulin resistance is a fundamental cause of the condition, and targeting it with AVANDIA could lead to better outcomes.